Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease

Amit Assa, Corina Hartman, Batia Weiss, Efrat Broide, Yoram Rosenbach, Noam Zevit, Yoram Bujanover, Raanan Shamir

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


Background: Anti tumor necrosis factor alpha (TNFα) agents have become widely used in pediatric inflammatory bowel disease (IBD). So far, only few studies examined the long-term results of anti-TNFα treatment in children with IBD. Methods: The long-term outcome of pediatric patients with IBD was assessed retrospectively in a multicenter cohort of children treated with anti-TNFα beyond induction treatment. Short- and long-term response rates, predictors for loss of response, data on growth and laboratory parameters were assessed. Results: 120 patients [101 crohn's disease (CD), 19 ulcerative colitis (UC) or indeterminate colitis (IC)] received either infliximab or adalimumab. The mean age at initiation of anti-TNFα was 13.4 ± 3.9 years and the median duration of anti-TNFα treatment was 15 months (range: 2-90). Overall, 89% of the cohort experienced short-term response following induction. Response was associated with improvement in weight and BMI Z-scores (p < 0.001) but not with linear growth. Responders experienced a significant decrease in erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) during treatment (p < 0.001). Albumin and hemoglobin both improved but only albumin increased significantly (p < 0.001).The cumulative probability of losing response to anti-TNFα treatment was 17%, 38%, and 49% after 1, 3, and 5. years, respectively. Responders had a significantly lower weight and BMI Z-scores at initiation of anti-TNFα treatment in compared to non-responders (p = 0.04 and 0.02 respectively). Conclusions: Our long term cohort supports the current evidence on the effectiveness and safety of anti-TNFα treatment in children with IBD. Response to treatment was interestingly associated with lower weight and BMI.

Original languageEnglish
Pages (from-to)369-376
Number of pages8
JournalJournal of Crohn's and Colitis
Issue number5
StatePublished - 1 Jun 2013
Externally publishedYes


  • Adalimumab
  • Growth
  • Inflammatory markers
  • Infliximab
  • Response

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease'. Together they form a unique fingerprint.

Cite this